Viridian Therapeutics Board Changes & Filings
Ticker: VRDN · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1590750
Sentiment: neutral
Topics: board-changes, filings, executive-compensation
TL;DR
Viridian Therapeutics board member exits, financial filings out.
AI Summary
Viridian Therapeutics, Inc. announced on April 2, 2025, the departure of Dr. Jonathan G. Drachman from its Board of Directors. The company also reported on compensatory arrangements for its named executive officers and filed financial statements and exhibits.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while the filing of financial statements provides crucial updates on the company's financial health.
Risk Assessment
Risk Level: low — The filing primarily concerns routine board changes and financial statement disclosures, with no immediate indication of significant operational or financial distress.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan G. Drachman (person) — Departing Board Member
- April 2, 2025 (date) — Date of earliest event reported
FAQ
Who is Dr. Jonathan G. Drachman and what was his role at Viridian Therapeutics?
Dr. Jonathan G. Drachman was a member of the Board of Directors of Viridian Therapeutics, Inc.
What is the significance of the filing of financial statements and exhibits?
The filing of financial statements and exhibits provides updated financial information and supporting documents for the company.
What other items are covered in this 8-K filing besides director departure?
The filing also covers the election of directors, appointment of certain officers, compensatory arrangements of certain officers, and Regulation FD Disclosure.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 2, 2025.
What is the company's state of incorporation and fiscal year end?
Viridian Therapeutics, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 by Dr. Jonathan G. Drachman regarding Viridian Therapeutics, Inc.\DE (VRDN).